Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT.

Paul J, Soujon M, Wengner AM, Zitzmann-Kolbe S, Sturz A, Haike K, Keng Magdalene KH, Tan SH, Lange M, Tan SY, Mumberg D, Lim ST, Ziegelbauer K, Liu N.

Cancer Cell. 2017 Jan 9;31(1):64-78. doi: 10.1016/j.ccell.2016.12.003.

2.

BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity.

Santag S, Siegel F, Wengner AM, Lange C, Bömer U, Eis K, Pühler F, Lienau P, Bergemann L, Michels M, von Nussbaum F, Mumberg D, Petersen K.

Cancer Lett. 2017 Apr 1;390:21-29. doi: 10.1016/j.canlet.2016.12.029. Epub 2016 Dec 31.

3.

Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.

Wengner AM, Siemeister G, Koppitz M, Schulze V, Kosemund D, Klar U, Stoeckigt D, Neuhaus R, Lienau P, Bader B, Prechtl S, Raschke M, Frisk AL, von Ahsen O, Michels M, Kreft B, von Nussbaum F, Brands M, Mumberg D, Ziegelbauer K.

Mol Cancer Ther. 2016 Apr;15(4):583-92. doi: 10.1158/1535-7163.MCT-15-0500. Epub 2016 Feb 1.

4.

Characterization of novel MPS1 inhibitors with preclinical anticancer activity.

Jemaà M, Galluzzi L, Kepp O, Senovilla L, Brands M, Boemer U, Koppitz M, Lienau P, Prechtl S, Schulze V, Siemeister G, Wengner AM, Mumberg D, Ziegelbauer K, Abrieu A, Castedo M, Vitale I, Kroemer G.

Cell Death Differ. 2013 Nov;20(11):1532-45. doi: 10.1038/cdd.2013.105. Epub 2013 Aug 9.

5.

The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer.

Lücking U, Jautelat R, Krüger M, Brumby T, Lienau P, Schäfer M, Briem H, Schulze J, Hillisch A, Reichel A, Wengner AM, Siemeister G.

ChemMedChem. 2013 Jul;8(7):1067-85. doi: 10.1002/cmdc.201300096. Epub 2013 May 13.

PMID:
23671017
6.

BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application.

Siemeister G, Lücking U, Wengner AM, Lienau P, Steinke W, Schatz C, Mumberg D, Ziegelbauer K.

Mol Cancer Ther. 2012 Oct;11(10):2265-73. doi: 10.1158/1535-7163.MCT-12-0286. Epub 2012 Jul 19.

7.

Adaptive peripheral immune response increases proliferation of neural precursor cells in the adult hippocampus.

Wolf SA, Steiner B, Wengner A, Lipp M, Kammertoens T, Kempermann G.

FASEB J. 2009 Sep;23(9):3121-8. doi: 10.1096/fj.08-113944. Epub 2009 May 11.

PMID:
19433626
8.

Differential mobilization of subsets of progenitor cells from the bone marrow.

Pitchford SC, Furze RC, Jones CP, Wengner AM, Rankin SM.

Cell Stem Cell. 2009 Jan 9;4(1):62-72. doi: 10.1016/j.stem.2008.10.017.

9.

The coordinated action of G-CSF and ELR + CXC chemokines in neutrophil mobilization during acute inflammation.

Wengner AM, Pitchford SC, Furze RC, Rankin SM.

Blood. 2008 Jan 1;111(1):42-9. Epub 2007 Oct 10.

10.

CXCR5- and CCR7-dependent lymphoid neogenesis in a murine model of chronic antigen-induced arthritis.

Wengner AM, Höpken UE, Petrow PK, Hartmann S, Schurigt U, Bräuer R, Lipp M.

Arthritis Rheum. 2007 Oct;56(10):3271-83.

11.

CCR7 deficiency causes ectopic lymphoid neogenesis and disturbed mucosal tissue integrity.

Höpken UE, Wengner AM, Loddenkemper C, Stein H, Heimesaat MM, Rehm A, Lipp M.

Blood. 2007 Feb 1;109(3):886-95. Epub 2006 Oct 3.

12.
13.

Degradation of oxidized extracellular proteins by microglia.

Stolzing A, Wengner A, Grune T.

Arch Biochem Biophys. 2002 Apr 15;400(2):171-9.

PMID:
12054427

Supplemental Content

Loading ...
Support Center